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Abstract
Background: Data from primary health care in Spain show a high prevalence of the major depressive disorder.
Blended treatment (combination of face-to-face and online components) seems to be a very promising tool for the
optimization and dissemination of psychological treatments in a cost-effective form. Although there is growing data
that confirm the advantages of blended therapies, few studies have analyzed their application in regular clinical
practice. The objective of the present paper is to describe the protocol for a clinical study aimed at exploring the
clinical and cost-effectiveness of a blended cognitive behavioral therapy (b-CBT) for depression, compared to
treatment as usual (TAU) in a primary health care setting.
Methods: A two-arm randomised controlled non-inferiority trial will be carried out, with repeated measures
(baseline, 3 months, 6 months, and 12 months) under two conditions: b-CBT and TAU. The b-CBT program will
consist in three face-to-face sessions and eight online sessions. The TAU is defined as the routine care delivered by
the general practitioner for the treatment of depression in primary care. The primary outcome is a symptomatic
change of depressive symptoms on the patient-health questionnaire (PHQ-9). Other secondary outcomes will be
considered (e.g., quality of life, treatment preference). All participants must be 18 years of age or older and meet
the diagnostic criteria for major depressive disorder according to the Diagnostic and Statistical Manual of Mental
disorders 4th edition. 156 participants will be recruited (78 per arm).
Discussion: It is expected that b-CBT is clinically non-inferior when compared to TAU. This is the first study in Spain
to use a b-CBT format in primary and specialized care, and this format could be an efficacious and cost-effective
therapeutic strategy for the treatment of depression.
Trial registration: ClinicalTrials.gov NCT02361684. Registered on 8 January 2015. Currently recruiting participants.
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Background
Depression is a highly prevalent disorder with consider-
able personal and social costs in terms of quality of life,
wellbeing, and economic effects [1–4]. In this regard,
the World Health Organization (WHO) predicts that de-
pression will be one of the three leading causes of the
burden of disease by 2030 [5, 6]. Even though there are
effective treatments for this emotional disorder (pharma-
cotherapy, psychotherapy or both) [7–9], these treat-
ments fail to reach the growing number of people who
need them [10]. Data from primary health care in Spain
reveal a high prevalence of mental disorders (with de-
pression at the top) [11–13] and an important gap be-
tween the number of people suffering from depression
and the rate of treatment received [14, 15]. Therefore, it
becomes necessary to incorporate new approaches into
the traditional ways of providing psychological treat-
ments, in order to effectively respond to this need [10,
16]. Internet-based treatments are a cost-effective alter-
native that can improve treatment dissemination, be-
coming a useful resource to address the gap between
treatment demand and supply. In recent years, several
studies have assessed the effectiveness and acceptability
of computer-based treatments for depression, obtaining
positive results [17–19]. Regarding efficacy, several sys-
tematic reviews have found that online treatments are
more effective when guided (ranging from automated re-
minders to encouragement and feedback by email, text
messages, or brief telephone calls) [20, 21], highlighting
the positive association between therapist contact and
improvement rates [22]. Some data also show that
guided self-help and face-to-face treatments do not sig-
nificantly differ in their effectiveness [23–25].
Due to the benefits of including therapist support in
Internet-delivered treatments, and seeking the best ap-
proach in terms of cost-efficacy, the “blended treatment”
format emerges as a good alternative to address the
growing need for access to evidence-based psychological
treatments for mental disorders. Blended treatment usu-
ally refers to the combination of face-to-face and online
components [26]. This format combines the best qual-
ities of each therapeutic approach: broader dissemin-
ation, less therapist time, lower health services costs,
and direct therapist-patient support and guidance, which
may lead to greater adherence. There are previous expe-
riences with this treatment format, with positive out-
comes in terms of efficacy, adherence, and relapse
prevention [27–31].
Despite the above, very little research has focused on
blended treatments in regular clinical practice (e.g.,
[32]). If the goal is to diminish the burden of mental dis-
orders and decrease the gap between treatment demand
and true access to psychological support, it is necessary
to assess the efficacy, feasibility, and cost-effectiveness of
these types of treatments. Therefore, the aim of the
present paper is to describe the protocol for a rando-
mised controlled non-inferiority trial that compares the
clinical and cost-effectiveness of blended cognitive be-
havioral therapy (b-CBT) for adults suffering from major
depressive disorder (MDD) and treatment as usual
(TAU) in a primary health care setting.
Methods
Aim
The aim of the study is to explore the clinical and cost-
effectiveness of a b-CBT for depression, compared to
TAU, in primary care in Spain. This trial is part of the E-
COMPARED project [European 7FP, N° Agreement;
603,098], which includes several randomised controlled
non-inferiority trials in both primary care and special-
ized care in eight European countries, in an effort to ob-
tain clinically significant data.
The hypothesis is that b-CBT will be at least as effect-
ive as the TAU condition, defined as the routine care
that patients receive in primary care in Spain when diag-
nosed with depression.
Study design
A two-arm randomised controlled non-inferiority and
cost-effectiveness trial will be carried out, with repeated
measures (baseline, 3 months, 6 months, and 12 months)
and two conditions: b-CBT and TAU. The study will be
conducted following the CONSORT statement (Consoli-
dated Standards of Reporting Trials, http://www.con-
sort-statement.org) [33, 34], the CONSORT-EHEALTH
guidelines [35], and the Recommendations for Interven-
tional Trials (SPIRIT) [36, 37].
Sample size
The sample size calculation is based on the non-
inferiority design and calculated for the primary clinical
outcome: depression symptoms (3 months after base-
line). Following Cohen [38], f = 0.20 represents an effect
size of small magnitude, which is a conservative estimate
of the subjective minimal important difference noted by
patients. Taking into account the E-COMPARED project
as a whole, and considering an alpha of 0.05 and a statis-
tical power of 0.90, the total sample size required to war-
rant these conditions is 1052 participants. Based on the
literature on Internet-based treatments, a 30% dropout
rate is expected [39]. Thus, the total number of partici-
pants to be recruited will be 1200, 150 patients in each
country involved in the project. However, in the case of
the trial in Spain, we intend to include 156 participants
(78 per arm). This sample size was calculated assuming
that there is no difference between standard and blended
depression treatment, considering a statistical power of
0.80, and that the lower limit of a one-sided 95%
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confidence interval will be above a non-inferiority limit
of − 0.4. A margin of 0.4 was judged acceptable, as this
range of a small to moderate difference in effect size will
not result in clinically important differences.
Study population, recruitment, and eligibility criteria
Participants who report depression to their general prac-
titioner (GP) will be consecutively invited to participate
in the trial. This recruitment will be implemented in pri-
mary care centers belonging to the Hospital of the Ri-
vera in Valencia, and the Provincial Hospital of Zamora.
All interested participants must give written informed
consent to take part in the trial. To confirm inclusion/
exclusion criteria (see Table 1), a telephone screening
interview will be carried out by a psychologist from the
University of Valencia and the University of Castellón,
using the MINI International Neuropsychiatric Interview
for diagnosis version 5 (M.I.N.I. 5.0) [40–42]. If the par-
ticipant meets the eligibility criteria, after completing the
baseline measurement, randomization will be conducted.
An independent researcher from VU University in
Amsterdam will create an allocation scheme using a
block randomization design (variable block sizes) with a
computerized random number generator (Random Allo-
cation Software) at an allocation ratio of 1:1. Participants
will be assigned to two conditions: b-CBT or TAU. The
condition to which they are assigned will be communi-
cated to the participants by telephone. Blinding for the
treatment is not possible because it will be clear to both
therapists and patients whether the treatment is blended
or not. The follow-up measurements will be adminis-
tered online and by telephone (3 months, 6 months, and
12 months). Figure 1 shows the study flow chart.
Ethics
The study follows the guidelines of the Helsinki Declar-
ation [43]. All the researchers will follow the guidelines
for Good Clinical Practice [44]. As noted, all the partici-
pants will be volunteers, and they will not receive any
compensation for their participation. They will sign the
informed consent once the study and its conditions have
been explained. Participants will be able to withdraw
from the study at any time, without giving any reason
and with no consequences. The study is registered in the
United States National Institute of Health Registration
System (http://www.clinicaltrials.gov) with Clinical Trials
Registration Number: NCT02361684, https://clinical-
trials.gov/ct2/show/NCT02361684.
Interventions
Blended cognitive behavioral therapy (b-CBT)
Cognitive Behavioral Therapy (CBT) is the most com-
monly used and recommended treatment due to its
Table 1 Inclusion/exclusion criteria
Inclusion Criteria Exclusion criteria
Minimum age of 18 years old Presence of serious psychiatric comorbidities (substance dependence, bipolar affective disorder,
obsessive compulsive disorder, psychotic illness)
Meeting the DSM-IV diagnostic criteria for
Major Depressive Disorder
High risk for suicide
Ability to understand and read Spanish Receiving psychological treatment for depression at the time of recruitment
Access to Internet and having an email address An increase and/or change in the pharmacological treatment (in the case of receiving it)
during the study period
Providing written informed consent Medical disease that prevents the participant from carrying out the psychological treatment
Fig. 1 Patient flow diagram
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favorable clinical outcomes in depression [45, 46]. It
usually focuses on four psychological components: 1)
psycho-education, 2) behavioral activation, 3) cognitive
therapy, and 4) relapse prevention. All E-COMPARED
interventions must provide these four core components,
and they can additionally provide two extra components.
All E-COMPARED project interventions combine in-
dividual CBT delivered through face-to-face sessions
(FTF) and online sessions. The ratio used is one FTF
session per three sessions delivered over the Internet.
The b-CBT will be provided by therapists (clinical psy-
chologists) who will receive special training in blended
CBT and how to deliver it. Therapists will receive a
manual with the corresponding procedure and content
for each FTF session. All therapists will have a minimum
of two years of work experience in Spanish mental
health care.
Regarding the intervention protocol, this b-CBT pro-
gram will be composed of three 45-min face-to-face ses-
sions and eight online sessions in 10 weeks.
Face-to-face sessions
The first FTF session will be held at the beginning of
the treatment. It will focus on clarifying the instruc-
tions for the use of the online platform, and motiv-
ation for life changes will be addressed. In the middle
of the intervention (module 6), participants will re-
ceive the second FTF session. The purpose of this
session is to resolve doubts about previous thera-
peutic contents and reinforce commitment and adher-
ence to treatment. The last FTF session is held at the
end of the entire program. This final session is dedi-
cated to analyzing possible difficulties and presenting
and discussing relapse prevention with the
participants. Between the FTF sessions, the following
four online sessions will be implemented.
Online treatment platform
The online part of this intervention corresponds to the
“Smiling is Fun” program [47, 48]. It is an Internet-
delivered, multimedia, interactive, self-help and self-
applied program for emotional disorders (e.g., depres-
sion). It follows a transdiagnostic perspective and is
based on CBT techniques. It is mainly designed to learn
and practice adaptive ways to cope with depression and
daily problems. It was developed within Project OPTIMI
(Online Predictive Tools for Intervention in Mental Ill-
ness), funded by the VII Program Framework of the
European Union. The program includes six treatment
components (motivation, psycho-education, behavioral
activation strategies, cognitive therapy, positive psych-
ology strategies, and relapse prevention) addressed
through eight modules. Each module and its specific ob-
jectives are shown in Table 2.
The program also includes two interactive tools that
accompany the patients during the intervention: 1)
The Activity diary provides feedback about mood, ac-
tivities performed, and their relationship, and it also
shows the mood benefits of being involved in mean-
ingful activities; 2) The “How am I?” section offers a
set of graphs and feedback to chart the user’s pro-
gress in terms of level of activity, emotional discom-
fort, and intensity of positive and negative
emotionality.
Moreover, the Internet platform includes a mobile
phone component that enables daily ecological moment-
ary assessment (EMA) of the participant’s mood state
(e.g., What is your mood right now?), cognitions (e.g.,
How much are you worrying at the moment?), activities
Table 2 Modules and objectives of “Smiling is Fun”
Module Objective
(1) Motivation for change Analyze the advantages and disadvantages of changing, emphasizing the importance
of being motivated.
(2) Understanding emotional
problems
Recognize and understand emotional problems.
(3) Learning to move on Teach the importance of “moving on” to acquire a proper level of activity and
involvement in life.
(4) Learning to be flexible Teach a more flexible way of thinking, interpreting situations, and learning to think
about different alternatives.
(5) Learning to enjoy Generate positive emotions, promoting the involvement in pleasant and significant
activities and contact with other people.
(6) Learning to live Understand the importance of identifying the individual’s own psychological strengths
and selecting and carrying out meaningful activities linked to values and goals in life.
(7) Living and learning Develop an action plan to boost individual psychological strengths.
(8) From now on, what
else…?
Go on and strengthen what has been learned during the program.
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(e.g., How much did you enjoy the activities today?), so-
cial interaction (e.g., How much were you involved in so-
cial interactions today?), and sleep (e.g., How well did
you sleep last night?). All the EMA measures will be
time and day stamped.
Treatment as usual (TAU)
TAU is defined as the routine care delivered by the gen-
eral practitioner for the treatment of depression in pri-
mary care. The type of treatment can vary depending on
the GP’s opinion and the severity of each patient. In
Spain, the intervention generally consists of antidepres-
sant medication. The specific type of treatment imple-
mented will be monitored.
Adherence
If participants do not enter the online platform (for
more than 15 days), they will receive emails reminding
them of the importance of reviewing the modules and
encouraging them to do the homework tasks. A profes-
sional platform will be used to send these emails
(www.psicologiaytecnologia.com). In addition, the thera-
pists will call the participants to schedule the FTF
sessions.
Measures
The study measures and assessment times (online and
by phone) are summarized in Table 3.
Primary outcome measures
Symptoms of depression
Patient Health Questionnaire-9 (PHQ-9) [49] will be
used as a primary outcome measure. It is a 9-item ques-
tionnaire that can be used to screen and diagnose pa-
tients with depressive disorders. The nine items are each
scored on a 0–3 scale. Total scores range from 0 to 27;
higher scores indicate more severe depression. The
PHQ-9 has been shown to have good psychometric
properties [50].
Secondary outcome measures
Diagnostic interview
The MINI International Neuropsychiatric Interview ver-
sion 5.0 (M.I.N.I. 5.0) [40–42] will be used at screening
to assess current depression and current comorbid dis-
orders. This measure is a structured diagnostic interview
based on the Diagnostic and Statistical Manual of Men-
tal Disorders 4th edition (DSM-IV) and on International
Classification of Diseases-10 (ICD-10) criteria.
Table 3 The study measures and assessment times
Variable Instrument Screening baseline 3 months 6 months 12 months
Online Phone Online Phone Online Phone Online Phone
Questions for patients
Demographics and history of
mental health treatments
x
Diagnostic interview M.I.N.I. x x
Symptoms of depression PHQ-9 QUIDS SR-16 x x x x
Quality of life EQ-5D-5 L AQol x x x x
Health care uptake and
productivity at work
TiC-P x x x x
Treatment preference x
Patient expectancy of
treatment
CEQ x
Working alliance WAI-SF x
Technology alliance TAI-OTa x
Client satisfaction CSQ x
Satisfaction with the online
program
SUSa x
Questions for therapists
Working alliance WAI-SF x
Satisfaction with the online
program
SUSa x
M.I.N.I MINI International Neuropsychiatric Interview, PHQ-9 Patient Health Questionnaire-9, QUIDS SR-16 Quick Inventory of Depressive Symptomatology-16, EQ-
5D-5 L EuroQol 5D, AQol Assessment of Quality of Life, TiC-P Trimbos and iMTA Questionnaires on Costs Associated with Psychiatric Illness, CEQ Credibility and
Expectancy Questionnaire, WAI-SF, Working Alliance Inventory, TAI-OT WAI Online Therapy, CSQ Client Satisfaction Questionnaire, SUS System Usability Scale
aThis instrument will be administered in the b-CBT condition
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Severity of depression
The Quick Inventory of Depressive Symptomatology-16
(QIDS SR-16) [51, 52]. This scale is a 16-item self-report
that assesses the severity of depression and nine symp-
tom domain criteria (sleep, sad mood, appetite-weight,
concentration-decision making, self-view, thoughts of
death or suicide, general interest, energy level, and rest-
lessness/agitation) that define a major depressive episode
according to the DSM-IV.
Quality of life
It will be measured with the EuroQol 5D (EQ-5D-5 L)
[53–55] and the Assessment of Quality of Life (AQol)
questionnaire [56]. The former is a self-report question-
naire that measures health-related quality of life and en-
ables conversion to utility scores to calculate Quality-
Adjusted Life-Years (QALYs) [57, 58]. This scale is com-
posed of five dimensions with 5 items related to anxiety
or depression: mobility, self-care, ordinary activities, dis-
comfort, and mood state. The AQol consists of 20 items
covering five dimensions that measure the “utility” of
health states: illness, independent living, social relation-
ships, physical senses, and psychological well-being. In
both instruments, the five categories are measured in a
range from “no problems” to “a lot of problems”.
Cost measures
Health care uptake and productivity at work
This will be evaluated with the Trimbos and iMTA
Questionnaire on Costs Associated with Psychiatric Ill-
ness (TiC-P) [59]. It is an 11-item self-report question-
naire with two different parts that can be administered
separately. Part I assesses the participant’s health care
and medication use. Part II measures lost productivity
costs resulting from absenteeism (being absent from
work because of illness) and presenteeism (being present
at work while ill, which may lead to reduced efficiency).
Other measures
Demographic variables and history of mental health
treatments
Personal data that include information such as age, gen-
der, country of birth, education level, and treatments re-
ceived for psychological problems.
Preference for treatment
The participants will indicate their treatment preference,
choosing between the b-CBT and TAU options (“If you
had the chance to choose your depression treatment,
which one would you prefer to receive?”).
Patient expectancy of treatment
This variable will be measured with the Credibility and
Expectancy Questionnaire by Devilly and Borkovec (CEQ)
[60]. This 6-item self-report instrument measures treat-
ment credibility and patient expectations of improvement.
Therapeutic alliance
This will be assessed using the short version of the
Working Alliance Inventory (WAI-SF) [61]. This inven-
tory is a 12-item (for patient) and 10-item (for therapist)
self-report questionnaire with responses given on a 5-
point Likert scale ranging from 1 (never) to 5 (always),
considering three dimensions: (1) therapeutic goals, (2)
tasks, and (3) bond. The alliance between the patient
and technologies will be assessed with the WAI Online
Therapy questionnaire (TAI-OT) developed by Labpsitec
(http://www.labpsitec.uji.es/esp/index.php).
Client satisfaction
The Client Satisfaction Questionnaire (CSQ) [62, 63] will
be used to assess overall patient satisfaction with health
and human services. It consists of 8 items measured on
a 4-point scale with total scores ranging from 8 to 32
points.
Satisfaction with the online program
To assess the overall usability of the online program, the
System Usability Scale (SUS) [64] will be used. It is a 10-
item scale, measured on a 5-point scale ranging from
strongly disagree to strongly agree. Total SUS scores
range from 0 to100. The questionnaire was found to be
reliable and robust [65].
Ecological momentary assessment (EMA)
Daily functioning
During the first and last week of treatment, twice a day
(morning and evening), participants will receive a set of
questions on their mobile phones about their mood state
(e.g., What is your mood right now?), cognitions (e.g.,
How much are you worrying at the moment?), activities
(e.g., How much did you enjoy activities today?), social
interaction (e.g., How much were you involved in social
interactions today?), and sleep (e.g., How well did you
sleep last night?). They will also receive them once a
week during treatment on a random day. In all cases,
participants will rate their answers on a 0–10 Likert
scale.
Analysis
Multiple imputation will be used to deal with missing
data. The primary statistical analyses will be group com-
parisons of improvements in depressive symptoms. An
analysis of covariance (ANCOVA) model with com-
pleters’ data will be used for this purpose. Intention-to-
treat analyses will be used in sensitivity analyses to in-
crease confidence in the results obtained. It is hypothe-
sized that blended depression treatment will be equally
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as effective as care-as-usual. A non-inferiority margin
and the smallest clinically acceptable difference will be
considered to exist when the two-sided 95% confidence
interval (the range of plausible differences between the
two treatments) lies entirely above the standard mean
difference of 0.20.
Discussion
The purpose of the present study protocol is to explore
the clinical effectiveness of a b-CBT for depression, com-
pared to treatment as usual, in Spanish primary care set-
tings. It is expected that the combination of FTF with
online sessions will be at least as effective as usual care
in improving depressive symptoms. Moreover, it is ex-
pected that the blended format, although somewhat
more demanding in terms of commitment of clinician
hours than a completely self-applied treatment, will be
an adequate way to deliver empirically validated treat-
ments, combining two key needs: the need for access
and treatment dissemination and the need for therapist
support during treatments. To our knowledge, this is the
first study in Spain to use a b-CBT format in primary
care settings, and this format could be an efficacious and
cost-effective therapeutic option for the treatment of
depression.
One of the strengths of the present study is the inclu-
sion of ecological momentary assessments throughout
the treatment period. This can be a relevant source of
information about participants’ evolution in terms of im-
provement and worsening and their association with
specific therapeutic components. Even though these data
may not be sufficient to analyze the isolated impact of
each program module (given the study design imple-
mented here), they will be a significant reflection of the
real usefulness and daily impact of this intervention on
the quality of life of the participants involved.
Another strength of the study is its focus on primary
health care, given the need to assess the real efficacy,
feasibility, and cost-effectiveness of blended treatments
in these settings, with the hope that they can become a
viable resource to respond to the increasing demand for
psychological care.
Regarding possible limitations, we can expect some
barriers and/or negative attitudes from the GPs about
recommending this treatment to their patients, and high
dropout rates in the treatment group can be expected
(around 30%), based on the literature [e.g., 39].
If the results of this study show the expected efficiency
and efficacy of b-CBT, this could be a first step in the
implementation of these treatment models in primary
care as a potential solution to different problems the
Healthcare system is facing at this time (such as the
need to reduce costs and increasing demand from pa-
tients). In conclusion, positive results of this study could
have a significant impact on primary care settings in the
National Health System in Spain and in society in
general.
Trial status
The study commenced recruitment in February 2015
and is currently recruiting.
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